Biogen Has Agreed To Acquire Human Immunology Biosciences For $1.15B Upfront And Up To $650M In Potential Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
Biogen has agreed to acquire Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in potential milestone payments. The acquisition includes felzartamab, an investigational anti-CD38 monoclonal antibody with potential in immune-mediated diseases. This move aims to enhance Biogen's capabilities in immunology and rare diseases.
May 22, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's acquisition of Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in milestone payments includes felzartamab, a promising therapeutic candidate. This acquisition aims to strengthen Biogen's position in immunology and rare diseases.
The acquisition of Human Immunology Biosciences and its promising therapeutic candidate felzartamab is likely to enhance Biogen's capabilities in immunology and rare diseases. This strategic move is expected to positively impact Biogen's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100